Register to Nordic AML Meeting, 24-25 August, 2023 in Bergen
REGISTRATION
Nordic AML Meeting 2023, August 24-25, Bergen – Norway
Preliminary program per March 16, 2023
_____________________________________________________________________
Day 1: Thursday August 24, 2023
09:45-10:00: Welcome and Opening: Bjørn Tore Gjertsen (Chair, Nordic AML Group)
Session 1: Chairs: Bjørn Tore Gjertsen, Jeffrey Tyner
10:00-10:30: NAMLG Keynote Lecture, Kimmo Porkka: Functional Precision Medicine for Acute Myeloid Leukemia
10:30-10:50: Jorrit Enserink: Drug sensitivity Screen in AML undergoing intensive chemotherapy
10:50-11:10: Krister Wennerberg: Repurposing through drug sensitivity screen in AML
11:10-11:30: Caroline Heckmann: Contextual factors in drug sensitivity screen
11:30-11:50: Päivi Östling: Harmonization of Drug sensitivity Screen
Session 2: Chair: Mika Kontro, Kim Theilgaard-Mönch
11:50-11:20: Martin Jädersten: Real world use of venetoclax
11:20-11:50: Kim Theilgaard-Mönch: Interim analysis of the NAMLG trial LD-VenEx
11:50-12:20: Keynote Lecture, Daniel A Pollyea: Venetoclax in AML: Current state of the art and future development
12:30-13:30: LUNCH BREAK
Session 3: Chairs: Sören Lehmann, Oscar Brück
13:30-13:50: Tom Erkers: Data driven hallmarks in AML
13:50-14:10: Thoas Fioretos: Next generation genomics in diagnostics of AML
14:10-14:40: Sören Lehmann: Chromatin structure in AML
14:50-15:30 COFFEE BREAK
Session 4: Chairs: Karl-Johan Malmberg, Oslo; Kimmo Porkka
15:30-16:00: Keynote Lecture, Satu Mustjoki: The cellular immunological landscape of AML
16:00-16:20: Karl-Johan Malmberg: NK immunotherapy in AML
16:20-16:50: Arjan A van de Loosdrecht: Dendritic cell vaccine in AML CR1 MRD+
16:50-17:10: Sébastien Walchli: CAR T in AML
18:10: RECEPTION IN HAAKONSHALLEN, BERGEN MUNCIPALITY
19:30: CONFERENCE DINNER
______________________________________________________________________
Day 2: Friday August 25, 2023
Session 5: Chairs: Anne-Sophie von Krogh, Marianne Tang Severinsen
08:15-08:45: Gunnar Juliusson: Challenges of the new AML classifications and guidelines
08:45 – 09:00: Discussion
09:00 – 09:30: Keynote Lecture, Gerwin Huls: AML therapy backbone and the future of targeted therapies
09:30 – 09:50: Hans Beier Ommen: Measurable residual disease monitoring
09:50 – 10:10: Marianne Tang Severinsen: Registries in AML and a Nordic cohort of AML
10:10 – 10:40: Oscar Brück: Data Lake and collection of data for real world epidemiology
10:40 – 11:10 COFFEE BREAK
Session 6: Chairs: Caroline Heckman
11:10 – 11:40: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB Lecture, NN
11:40 – 12:00: Mika Kontro: Novel macrophage re-programmer bexmarilimab in myeloid malignancies
12:00 –12:30: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB Lecture, Jeffrey Tyner: Big data for novel therapeutic strategies in myeloid malignancies
12:30 – 13:30: LUNCH BREAK
Session 7: Chairs: James Lorens, Bergen; Satu Mustjoki
13:30 – 14:00: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB, Sonia Loges: AXL in AML
14:00 – 14:15: Bjørn Tore Gjertsen: Bemcentinib in cell fate modulation
14:15 – 14:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB Lecture, Uwe Platzbecker: Bemcentinib and Axl in MDS and AML.
Session 8: Chair: Pia Ettala, Vladimir Lazarevic
14:45 – 15:15: Martin Höglund: The therapeutic landscape in the Nordics: fit and unfit patients in a regional collaboration
15:15 – 15:45: COFFEE BREAK
Session 9: Chairs: Jean Christoph Bourdon, Dundee; Päivi Myllynen
15:45 – 16:15: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB, Eva Hellström-Lindberg: TP53 mutations in MDS and AML
16:15 – 16:45: Sören Lehmann: TP53 mutations – challenges and possibilities in AML
16:45 – 17:00: Closing remarks: Mika Kontro, Secretary, NAMLG